256,665 Shares in Krystal Biotech, Inc. $KRYS Bought by Jupiter Topco LLC

Jupiter Topco LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 256,665 shares of the company’s stock, valued at approximately $95,387,000. Jupiter Topco LLC owned 0.87% of Krystal Biotech as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of KRYS. Elmind Capital LP acquired a new position in shares of Krystal Biotech in the 2nd quarter valued at $8,176,740,000. ADAR1 Capital Management LLC purchased a new stake in Krystal Biotech during the second quarter valued at about $6,103,000. Hsbc Holdings PLC purchased a new stake in Krystal Biotech during the second quarter valued at about $3,653,000. EFG International AG purchased a new stake in Krystal Biotech during the second quarter valued at about $5,688,000. Finally, Palisade Capital Management LP acquired a new position in shares of Krystal Biotech in the second quarter worth about $3,741,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on KRYS. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Bank of America lifted their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. HC Wainwright boosted their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research note on Tuesday, June 16th. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $365.40.

Insiders Place Their Bets

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director owned 50,000 shares in the company, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 51,000 shares of company stock valued at $16,278,020 over the last ninety days. Corporate insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Up 1.0%

Shares of NASDAQ:KRYS opened at $359.76 on Thursday. The firm has a fifty day moving average of $348.38 and a two-hundred day moving average of $303.24. The firm has a market capitalization of $10.65 billion, a P/E ratio of 45.08 and a beta of 0.53. Krystal Biotech, Inc. has a 12-month low of $136.73 and a 12-month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The business had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Equities research analysts expect that Krystal Biotech, Inc. will post 7.68 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.